L&K Biomed, CEO Park Geun-ju and Executives Purchase Company Shares

[Asia Economy Reporter Hyungsoo Park] L&K Biomed announced on the 9th that six key executives, including CEO Park Geun-ju, purchased approximately 12,000 shares of the company's stock on the open market.

Considering that Chairman Kang Guk-jin purchased about 40,000 shares last month, the total number of shares held by the executives amounts to approximately 52,000 shares. The shares held by Chairman Kang and his related parties increased to 2,004,376 shares (14.97%).

A company official stated, "The 'stock ownership campaign' by key executives was carried out under the judgment that the stock price was undervalued, demonstrating their commitment to responsible management," adding, "We will continue to implement shareholder-friendly policies and sustain growth through performance improvement."

The official also added, "Starting in April, we will restore corporate and shareholder value through aggressive marketing via our local subsidiary in the United States."

In his New Year's address, CEO Park Geun-ju emphasized the phrase ‘必死則生, 必生則死 (Desperate efforts lead to survival, survival leads to death),’ expressing the firm determination of employees and executives to turn a profit in the company's 14th anniversary year.

L&K Biomed, marking this year as the first year of management normalization, is undertaking corporate restructuring efforts to achieve its business goals: ▲establishing a cost reduction system through management system improvements ▲developing new products and obtaining FDA approval using L&K’s technology ▲maximizing sales and operating profit through overseas market expansion.

This content was produced with the assistance of AI translation services.